Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441583 | 0.81 | HDAC4 (0.47) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL8137247 | 0.81 | ESR1 (0.50) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL78619 | 0.81 | HDAC4 (0.47) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| Formaldehyde SCHEMBL27512785 | 0.80 | HDAC4 (0.47) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL6678970 | 0.79 | CYP19A1 (0.45) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL6725277 | 0.79 | KIF11 (0.40) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL12811806 | 0.79 | ALDH1A1 (0.43) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL11469047 | 0.79 | CYP19A1 (0.43) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL8633370 | 0.79 | CYP19A1 (0.43) | CYP19A1KIF11ALDH1A1TSHRSCN5A | |
| SCHEMBL21791918 | 0.77 | CYP19A1 (0.42) | CYP19A1KIF11ALDH1A1TSHRSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037878-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999026927-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-2024089159-A1 | MAIN PROTEASE INHIBITORS | UBIQ HOLDING B.V. (NL) | 2024-05-02 | — | — | WO | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115698035-A | Inhibitors of norovirus and coronavirus replication | 共晶制药公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-2536716-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-12-26 | — | — | EP | disclosed |
| EP-2513096-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-A MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20100234220-A1 | Oxooxetanes as Fungicidal Agents | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | CYP19A1 3170/4885KIF11 1815/4885ALDH1A1 1895/4885 |
| US-20100234220-A1 | Oxooxetanes as Fungicidal Agents | CYP51A1, PNPO, AOX1 | CYP19A1 42/4885KIF11 4120/4885ALDH1A1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.